Multicenter, rAndomized, Double-blind, Placebo-conTrolled, 52-week stUdy to demonstRatE the Efficacy, Safety and Tolerability of Secukinumab Injections With 2 mL Auto-injectors (300 mg) in Adult Subjects With Plaque Psoriasis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms MATURE
Sponsors Novartis Pharmaceuticals

Most Recent Events

10 Sep 2019 Status changed from recruiting to active, no longer recruiting.
16 Jul 2019 Planned End Date changed from 22 Jun 2020 to 4 Sep 2020.
16 Jul 2019 Planned primary completion date changed from 26 Sep 2019 to 21 Nov 2019.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight